Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63380 | 0.92 | CXCR4 (0.41) | ALDH1A1KDM4ELMNATSHRUSP2 | |
| SCHEMBL62373 | 0.90 | MAPT (0.38) | KDM4ELMNAMAPTKMT2ACNR1 | |
| SCHEMBL61550 | 0.89 | C5AR1 (0.35) | KDM4EMAPTMEN1KMT2AMAPK1 | |
| SCHEMBL63649 | 0.88 | TSHR (0.45) | ALDH1A1KDM4EPOLBLMNATSHR | |
| SCHEMBL27666516 | 0.88 | S1PR5 (0.41) | ALDH1A1KDM4EPOLBLMNATSHR | |
| SCHEMBL62164 | 0.87 | CYP2A13 (0.41) | ALDH1A1KDM4EPOLBLMNATSHR | |
| SCHEMBL62979 | 0.86 | LMNA (0.43) | ALDH1A1KDM4EPOLBLMNATSHR | |
| SCHEMBL61650 | 0.86 | HTT (0.42) | ALDH1A1KDM4ELMNAMAPTSMN1; SMN2 | |
| SCHEMBL27666561 | 0.86 | POLB (0.41) | ALDH1A1KDM4EPOLBLMNATSHR | |
| SCHEMBL61686 | 0.85 | ALDH1A1 (0.51) | ALDH1A1KDM4EPOLBTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | claimed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | claimed |
| EP-1745033-A4 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORP (US) | 2009-08-26 | — | — | EP | claimed |
| EP-1745033-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | claimed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | claimed |
| WO-2005110416-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | claimed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-8129395-B2 | 4,5-disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-03-06 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-01-28 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482350-B2 | 4,5-disubstituted-2-aryl pyrimidines | NEUROGEN CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C3AR1, C5AR1 | ALDH1A1 1616/4885KDM4E 2238/4885POLB 3973/4885 |
| US-20100022516-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C5AR1, C3AR1 | ALDH1A1 1684/4885KDM4E 2149/4885POLB 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.